Ladostigil

DB16213InvestigationalSmall molecule

Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).

Formula / weight: C₁₆H₂₀N₂O₂ · 272.348 g/mol (avg)
Also known as: Tv-3326 free base

Resolves to

Compound

UNIISW3H1USR4QCAS209394-27-4ChEMBLCHEMBL255231

Structure

InChIKeyLHXOCOHMBFOVJS-OAHLLOKOSA-NSMILESCCN(C)C(=O)OC1=CC2=C(CC[C@H]2NCC#C)C=C1

Targets

P22303ACHEP21397MAOAP27338MAOB

What you can answer from here — as of January 29, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ladostigil, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account